The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1
|
作者：
Chen, Xi [1 ]
Wei, Xinyu [1 ]
Yao, Peizhuo [1 ]
Liu, Yanbin [1 ]
Guan, Haitao [2 ]
Kang, Huafeng [2 ]
Liu, Di [2 ]
Diao, Yan [2 ]
Ma, Xiaobin [2 ]
Min, Weili [2 ]
Shan, Changyou [2 ]
Zhao, Yang [2 ]
Zhao, Fang [2 ]
Chen, Yuanyuan [3 ]
Xiao, Dong [4 ]
She, Qing [3 ]
Liu, Youhuai [3 ]
Zhang, Yinbin [2 ]
Zhang, Shuqun [2 ]
机构：
[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China
[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China
来源：
CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期
关键词：
1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;
D O I：
10.1016/j.clbc.2024.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 202
页数：8
相关论文
共 50 条
  • [1] A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.
    Fasching, Peter A.
    Hartkopf, Andreas
    Kolberg, Hans-Christian
    Haeberle, Lothar
    Wetzig, Sarah
    Mau, Christine
    Engler, Tobias
    Ruebner, Matthias
    Huebner, Hanna
    Theuser, Anna-Katharin
    Hummel, Nadine
    Uhrig, Sabrina
    Beckmann, Matthias W.
    Hein, Alexander
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: an open-label, single-arm phase II study
    Liu, Yin
    Fan, Lei
    Shao, Zhi-Ming
    Wang, Zhong-Hua
    CANCER RESEARCH, 2023, 83 (05)
  • [3] A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
    Tanaka, N.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Jibiki, N.
    Yukawa, H.
    Matsuoka, A.
    Kodera, A.
    Kamimura, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [4] Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study
    Zhang, G.
    He, Y.
    Luo, D.
    Zhang, X.
    Gao, B.
    Jiang, Y.
    Zhao, J.
    Guo, L.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1414 - S1414
  • [5] Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial
    Zhang, Liulu
    Wu, Zhi-Yong
    Li, Jie
    Lin, Ying
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ci-Qiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 654 - 662
  • [6] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
    Zhang, Liulu
    Wu, Zhiyong
    Lin, Ying
    Li, Jie
    Liu, Zhenzhen
    Cao, Yin
    Zhang, Gangling
    Gao, Hong-Fei
    Yang, Mei
    Yang, Ci-Qiu
    Zhu, Teng
    Cheng, Min-Yi
    Ji, Fei
    Li, Jieqing
    Wang, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
    Ferreira, Arlindo R.
    Metzger-Filho, Otto
    Sarmento, Roberta M. B.
    Bines, Jose
    FRONTIERS IN ONCOLOGY, 2018, 7
  • [9] Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
    Chen, Zhiwei
    Shen, Shengping
    Shi, Wenbo
    Jiang, Gening
    Wang, Xin
    Jian, Hong
    Zhou, Zhen
    Ding, Zhengping
    Lu, Shun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6543 - 6552
  • [10] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
12345